[go: up one dir, main page]

BR112018071547A2 - acetil-leucina ou um sal farmaceuticamente aceitável desta - Google Patents

acetil-leucina ou um sal farmaceuticamente aceitável desta

Info

Publication number
BR112018071547A2
BR112018071547A2 BR112018071547-6A BR112018071547A BR112018071547A2 BR 112018071547 A2 BR112018071547 A2 BR 112018071547A2 BR 112018071547 A BR112018071547 A BR 112018071547A BR 112018071547 A2 BR112018071547 A2 BR 112018071547A2
Authority
BR
Brazil
Prior art keywords
pharmaceutically acceptable
acceptable salt
acetyl leucine
leucine
acetyl
Prior art date
Application number
BR112018071547-6A
Other languages
English (en)
Inventor
Factor Mallory
Strupp Michael
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of BR112018071547A2 publication Critical patent/BR112018071547A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

a presente divulgação é direcionada para acetil-leucina, ou um sal farmaceuticamente aceitável desta, para uso na melhora da função cognitiva, da mobilidade, ou da função cognitiva e da mobilidade em um sujeito, por exemplo, em um sujeito idoso.
BR112018071547-6A 2016-04-19 2017-04-19 acetil-leucina ou um sal farmaceuticamente aceitável desta BR112018071547A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201606834 2016-04-19
GB1606834.8 2016-04-19
PCT/GB2017/051090 WO2017182802A1 (en) 2016-04-19 2017-04-19 Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function

Publications (1)

Publication Number Publication Date
BR112018071547A2 true BR112018071547A2 (pt) 2019-03-06

Family

ID=58633040

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018071547-6A BR112018071547A2 (pt) 2016-04-19 2017-04-19 acetil-leucina ou um sal farmaceuticamente aceitável desta

Country Status (26)

Country Link
US (3) US10905670B2 (pt)
EP (2) EP4501406A3 (pt)
JP (3) JP7387264B2 (pt)
KR (4) KR20180134398A (pt)
CN (2) CN109069463B (pt)
AU (2) AU2017252507B2 (pt)
BR (1) BR112018071547A2 (pt)
CA (1) CA3021155A1 (pt)
DK (1) DK3445351T3 (pt)
ES (1) ES2994242T3 (pt)
FI (1) FI3445351T3 (pt)
HR (1) HRP20241552T1 (pt)
HU (1) HUE069219T2 (pt)
IL (3) IL310508A (pt)
LT (1) LT3445351T (pt)
MD (1) MD3445351T2 (pt)
MX (2) MX388461B (pt)
PL (1) PL3445351T3 (pt)
PT (1) PT3445351T (pt)
RS (1) RS66142B1 (pt)
RU (1) RU2745912C2 (pt)
SG (2) SG11201809031XA (pt)
SI (1) SI3445351T1 (pt)
SM (1) SMT202400459T1 (pt)
WO (1) WO2017182802A1 (pt)
ZA (1) ZA201806849B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3445351T1 (sl) * 2016-04-19 2025-04-30 Intrabio Ltd Acetil levcin ali njegova farmacevtsko sprejemljiva sol za izboljšanje gibljivosti
IL310801A (en) 2016-08-11 2024-04-01 Intrabio Ltd Acetyl-leucine for use in the treatment of neurodegenerative diseases
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
BR112021010923A2 (pt) 2018-12-06 2021-08-24 Intrabio Ltd Análogos deuterados de acetileucina
LT3934637T (lt) * 2019-03-02 2024-08-26 Intrabio Ltd (n-)acetil-l-leucinas, skirtas panaudoti trauminio smegenų pažeidimo gydymui
US20250099355A1 (en) 2023-07-18 2025-03-27 Sytheon Ltd Amino acid based salts, compositions and methods for treating skin and improving skin rejuvenation and longevity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060063827A1 (en) * 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
US20070190070A1 (en) * 2004-09-03 2007-08-16 Zeldis Jerome B Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
FR2905600B1 (fr) * 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
US20080097606A1 (en) * 2006-10-19 2008-04-24 Cragg Andrew H Knee joint prosthesis and hyaluronate compositions for treatment of osteoarthritis
US20120196257A1 (en) * 2009-08-27 2012-08-02 Joe Verghese Cognitive function training to improve motor ability
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
WO2012060844A1 (en) * 2010-11-05 2012-05-10 Biotie Therapies, Inc A2a antagonists as cognition and motor function enhancers
SI3445351T1 (sl) * 2016-04-19 2025-04-30 Intrabio Ltd Acetil levcin ali njegova farmacevtsko sprejemljiva sol za izboljšanje gibljivosti
EP3697406A1 (en) * 2017-10-18 2020-08-26 IntraBio Ltd Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders

Also Published As

Publication number Publication date
IL310508A (en) 2024-03-01
IL293266B1 (en) 2024-03-01
MX2021014844A (es) 2022-01-18
ES2994242T3 (en) 2025-02-05
KR20180134398A (ko) 2018-12-18
DK3445351T3 (da) 2024-11-04
KR20220038814A (ko) 2022-03-29
RU2018140131A (ru) 2020-05-14
EP3445351B1 (en) 2024-10-16
IL293266B2 (en) 2024-07-01
JP2019513814A (ja) 2019-05-30
JP2024123087A (ja) 2024-09-10
CA3021155A1 (en) 2017-10-26
IL293266A (en) 2022-07-01
KR102413754B1 (ko) 2022-06-27
WO2017182802A1 (en) 2017-10-26
IL262379A (en) 2018-11-29
EP4501406A2 (en) 2025-02-05
HUE069219T2 (hu) 2025-02-28
US20210106548A1 (en) 2021-04-15
PT3445351T (pt) 2024-11-14
MX388461B (es) 2025-03-20
AU2022256077A1 (en) 2022-11-17
AU2017252507B2 (en) 2022-07-21
CN109069463B (zh) 2024-07-23
KR20220093386A (ko) 2022-07-05
US12329733B2 (en) 2025-06-17
SG10202106190RA (en) 2021-07-29
KR102632670B1 (ko) 2024-02-01
CN109069463A (zh) 2018-12-21
AU2017252507A1 (en) 2018-11-08
JP7387264B2 (ja) 2023-11-28
JP7506046B2 (ja) 2024-06-25
JP2022024058A (ja) 2022-02-08
US10905670B2 (en) 2021-02-02
EP4501406A3 (en) 2025-03-26
PL3445351T3 (pl) 2025-01-07
MD3445351T2 (ro) 2024-12-31
RU2018140131A3 (pt) 2020-05-14
KR20240018683A (ko) 2024-02-13
KR102791288B1 (ko) 2025-04-03
LT3445351T (lt) 2024-11-25
RU2745912C2 (ru) 2021-04-02
SG11201809031XA (en) 2018-11-29
US20230346732A1 (en) 2023-11-02
SMT202400459T1 (it) 2025-01-14
US20190083438A1 (en) 2019-03-21
ZA201806849B (en) 2019-07-31
CN118593463A (zh) 2024-09-06
IL262379B (en) 2022-07-01
FI3445351T3 (fi) 2024-11-18
SI3445351T1 (sl) 2025-04-30
HRP20241552T1 (hr) 2025-01-17
US11998518B2 (en) 2024-06-04
MX2018012739A (es) 2019-06-17
RS66142B1 (sr) 2024-12-31
RU2021107001A (ru) 2021-04-12
EP3445351A1 (en) 2019-02-27

Similar Documents

Publication Publication Date Title
BR112018071547A2 (pt) acetil-leucina ou um sal farmaceuticamente aceitável desta
CL2018002012A1 (es) Derivados de maitansinoide, conjugados de los mismos y métodos de uso.
SV2018005610A (es) Derivados de oxopiridina sustituidos
BR112018073574A2 (pt) conjugados de anticorpo-fármaco anti-cmet e métodos para a sua utilização
BR112016018891A2 (pt) anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma
BR112017011316A2 (pt) derivados heterocíclicos e uso destes
BR112016026993A2 (pt) combinação de um anticorpo anti-ccr4 e um agonista 4-1bb para tratar câncer
TWD179096S (zh) 旋轉致動器之部分
TWD178500S (zh) 護膚器
TWD172100S (zh) 化粧瓶
CL2015003690A1 (es) Uso de pridopidina o una sal de la misma para preparar un medicamento útil en el tratamiento de la enfermedad de huntington.
BR112015021521A2 (pt) anticorpos anti-crth2 e métodos para seu uso
BR112017004141B8 (pt) Agente de imagemamento e seu uso
TWD180744S (zh) 旋轉致動器之部分
BR112019002730A2 (pt) acetil-leucina, ou um sal farmaceuticamente aceitável da mesma, para uso em um método de tratamento de uma doença neurodegenetativa
MX386055B (es) Uso de medicamentos para disminuir la evolución de la enfermedad de parkinson.
BR112015030399A2 (pt) derivados heterocíclicos e uso dos mesmos
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
CL2015002180A1 (es) Terapia de combinación para el tratamiento de neumonía nosocomial
BR112017007414A2 (pt) combinações compreendendo siponimod e laquinimod para o tratamento de esclerose múltipla
BR112017004136A2 (pt) sondas para imageamento de proteína de huntingtina
BR112016017620A2 (pt) Composto esteroidal para uso no tratamento da encefalopatia hepática
BR112017004134A2 (pt) ?sondas para imageamento de proteína de huntingtina?
BR112017015159A2 (pt) preparação e uso de produtos plaquetários
DOP2017000014A (es) Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122024012307-0 PROTOCOLO 870240051139 EM 17/06/2024 16:55.

B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]